πŸ‡ΊπŸ‡Έ FDA
Patent

US 7943659

MAPK/ERK kinase inhibitors

granted A61PA61P1/00A61P1/18

Quick answer

US patent 7943659 (MAPK/ERK kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 17 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P1/00, A61P1/18, A61P11/06, A61P13/08